Ranibizumab (Lucentis, Novartis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion has now been published. This is after three appraisal committee meetings and a big piece of work for the DSU looking at issues related to quality, use, efficacy and safety of bevacizumab in eye conditions.
Ranibizumab is recommended as an option for treating visual impairment caused by macular oedema following central retinal vein occlusion or following branch retinal vein occlusion only if treatment with laser photocoagulation has not been beneficial, and if the manufacturer provides ranibizumab with the discount agreed in the patient access scheme revised in the context of NICE technology appraisal guidance.
